Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 14/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235218 | 0.96 | CCR8 (0.59) | CCR8KCNH2CHRM2CHRM3HTR1A | |
| SCHEMBL4233147 | 0.89 | CCR8 (0.53) | CCR8KCNH2CHRM2CHRM3HTR1A | |
| SCHEMBL4237303 | 0.86 | CCR8 (0.64) | CCR8KCNH2CHRM2CHRM3USP2 | |
| Trifluoroacetic Acid SCHEMBL4237963 | 0.85 | CCR8 (0.59) | CCR8KCNH2CHRM2CHRM3USP2 | |
| Trifluoroacetic Acid SCHEMBL4230125 | 0.84 | CCR8 (0.60) | CCR8KCNH2CHRM2CHRM3USP2 | |
| Trifluoroacetic Acid SCHEMBL4239233 | 0.84 | CCR8 (0.60) | CCR8KCNH2CHRM2CHRM3USP2 | |
| Trifluoroacetic Acid SCHEMBL4238914 | 0.82 | CCR8 (0.69) | CCR8KCNH2CHRM2CHRM3USP2 | |
| SCHEMBL4234755 | 0.81 | CCR8 (0.62) | CCR8KCNH2CHRM2CHRM3USP2 | |
| Trifluoroacetic Acid SCHEMBL4234518 | 0.81 | CCR8 (0.69) | CCR8KCNH2USP2TSHRCYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4235417 | 0.80 | CCR8 (0.59) | CCR8KCNH2USP2TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | CCR8 1/4885KCNH2 3143/4885CHRM2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.